Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin + KPd in Relapsed Multiple Myeloma
NCT05789303Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- May 2023
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of belantamab mafodotin in multiple myeloma (MM) (2 cohorts), sponsored by University of Chicago. Primary endpoints: Rate of Very Good Partial Response and Rate of Overall Response. Started May 2023; status: recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05789303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05789303.